This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wu, K. Articles by Shi, Y. E. Search for Related Content PubMed PubMed Citation Articles by Wu, K. Articles by Shi, Y. E.

Stage-specific Expression of Breast Cancer-specific Gene -Synuclein¹

Departments of Surgery [K. W., Z. W., H. Q., Y. Z.] and Pathology [X. W.], XinHua Hospital affiliated with Shanghai Second Medical University; Institute of Biochemistry and Cell Biology, Chinese Academy of Science, Shanghai, China [Q. T., G. L., X. D.]; and Long Island Jewish Medical Center, Albert Einstein College of Medicine, New Hyde Park, New York 11040 [Y. J., Y. E. S.]

-Synuclein (SNCG), also referred as breast cancer-specific gene 1, is the third member of a neuronal protein family synuclein. SNCG is highly expressed in human-infiltrating breast carcinomas but not expressed in normal or benign breast tissues. To evaluate the clinical relevance of SNCG expression in breast cancer progression and its correlation with clinical parameters, we analyzed SNCG expression in 79 clinical breast specimens from primary breast cancer, hyperplasia, and fibroadenoma patients by reverse transcription-PCR. The status of estrogen receptor, progesterone receptor, proliferating cell nuclear antigen, and C-erBb2 was also analyzed by immunohistochemistry. Overall SNCG mRNA expression was detectable in 38.8% of breast cancers. However, 79% of stage III/IV breast cancers were positive for SNCG expression, whereas only 15% of stage I/II breast cancers were positive for SNCG expression. In contrast, the expression of SNCG was undetectable in all benign breast lesions. The expression of SNCG was strongly correlated to the stage of breast cancer (P = 0.000). This study suggests that the expression of SNCG is stage specific for breast cancer. SNCG is expected to be a useful marker for breast cancer progression and a potential target for breast cancer treatment.

This article has been cited by other articles:

				M. Ahmad, S. Attoub, M. N. Singh, F. L. Martin, and O. M. A. El-Agnaf {gamma}-Synuclein and the progression of cancer FASEB J, November 1, 2007; 21(13): 3419 - 3430. [Abstract] [Full Text] [PDF]

				V. K. Singh, Y. Zhou, J. A. Marsh, V. N. Uversky, J. D. Forman-Kay, J. Liu, and Z. Jia Synuclein-{gamma} Targeting Peptide Inhibitor that Enhances Sensitivity of Breast Cancer Cells to Antimicrotubule Drugs Cancer Res., January 15, 2007; 67(2): 626 - 633. [Abstract] [Full Text] [PDF]

				H. Liu, W. Liu, Y. Wu, Y. Zhou, R. Xue, C. Luo, L. Wang, W. Zhao, J.-D. Jiang, and J. Liu Loss of Epigenetic Control of Synuclein-{gamma} Gene as a Molecular Indicator of Metastasis in a Wide Range of Human Cancers Cancer Res., September 1, 2005; 65(17): 7635 - 7643. [Abstract] [Full Text] [PDF]

				M. J. Naylor, S. R. Oakes, M. Gardiner-Garden, J. Harris, K. Blazek, T. W. C. Ho, F. C. Li, D. Wynick, A. M. Walker, and C. J. Ormandy Transcriptional Changes Underlying the Secretory Activation Phase of Mammary Gland Development Mol. Endocrinol., July 1, 2005; 19(7): 1868 - 1883. [Abstract] [Full Text] [PDF]

				D. Cui, G. Jin, T. Gao, T. Sun, F. Tian, G. G. Estrada, H. Gao, and A. Sarai Characterization of BRCAA1 and Its Novel Antigen Epitope Identification Cancer Epidemiol. Biomarkers Prev., July 1, 2004; 13(7): 1136 - 1145. [Abstract] [Full Text] [PDF]

				Y. Jiang, Y. E. Liu, I. D. Goldberg, and Y. E. Shi {gamma} Synuclein, a Novel Heat-Shock Protein-Associated Chaperone, Stimulates Ligand-Dependent Estrogen Receptor {alpha} Signaling and Mammary Tumorigenesis Cancer Res., July 1, 2004; 64(13): 4539 - 4546. [Abstract] [Full Text] [PDF]